Immunological responses to pneumococcal vaccine in frail older people

Advanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody responses that increase the risk of invasive pneumococcal disease (IPD) and limit the effectiveness of vaccines. However, the elderly are a heterogeneou...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 27; no. 10; pp. 1628 - 1636
Main Authors Ridda, I., MacIntyre, C.R., Lindley, R., Gao, Z., Sullivan, J.S., Yuan, F.F., McIntyre, P.B.
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 04.03.2009
Elsevier
Elsevier Limited
Subjects
Online AccessGet full text
ISSN0264-410X
1873-2518
DOI10.1016/j.vaccine.2008.11.098

Cover

Loading…
Abstract Advanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody responses that increase the risk of invasive pneumococcal disease (IPD) and limit the effectiveness of vaccines. However, the elderly are a heterogeneous group and measures of overall frailty may be a better indicator of disease susceptibility (or vaccine response) than chronological age alone. To evaluate the immunogenicity of the 7-valent conjugated pneumococcal vaccine (PCV7) versus 23-valent polysaccharide vaccine (23vPPV) and compare the immune response to four serotypes (4, 6B, 18C and 19F), with respect to age or frailty in an elderly population of previously unvaccinated hospitalized patients. 241 patients aged 60 years and over, recruited between 16 May 2005 and 20 February 2006, were randomised to 23PPV or PCV7 vaccine. We measured Frailty Index (FI), Barthel index and the MiniMental State. Serotype-specific IgG was measured by ELISA at base line and 6 months after vaccination. Antibody responses were defined by the ratio of post-vaccination to pre-vaccination IgG antibody concentration (poor < 2-fold increase, acceptable ≥ 2.0 to 3.99-fold and strong ≥ 4.0-fold increase). Pre-immunization IgG was generally low and did not differ significantly by age or frailty. Post-immunization, IgG increased to all four serotypes; acceptable or strong response ranged between 29% for (6B) and 57% for (18C). There was no significant difference between the two vaccine types (23PPV versus PCV7). At 6 months post-vaccination, the highest geometric mean IgG concentrations (GMCs) were seen for serotype 19F and the lowest for serotype 4. Although there was some variation by serotype, responses after vaccination were lowest in the most frail or aged subjects. Pneumococcal vaccines are perceived to offer low protection in the frail elderly, but our study showed that the proportion of this vulnerable population with acceptable responses is encouraging. Frailty, as measured by the Frailty Index, appears to be a better predictor of immune response to pneumococcal vaccines than age alone.
AbstractList Advanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody responses that increase the risk of invasive pneumococcal disease (IPD) and limit the effectiveness of vaccines. However, the elderly are a heterogeneous group and measures of overall frailty may be a better indicator of disease susceptibility (or vaccine response) than chronological age alone. Aim To evaluate the immunogenicity of the 7-valent conjugated pneumococcal vaccine (PCV7) versus 23-valent polysaccharide vaccine (23vPPV) and compare the immune response to four serotypes (4, 6B, 18C and 19F), with respect to age or frailty in an elderly population of previously unvaccinated hospitalized patients. Method 241 patients aged 60 years and over, recruited between 16 May 2005 and 20 February 2006, were randomised to 23PPV or PCV7 vaccine. We measured Frailty Index (FI), Barthel index and the MiniMental State. Serotype-specific IgG was measured by ELISA at base line and 6 months after vaccination. Antibody responses were defined by the ratio of post-vaccination to pre-vaccination IgG antibody concentration (poor<2-fold increase, acceptable>=2.0 to 3.99-fold and strong>=4.0-fold increase). Results Pre-immunization IgG was generally low and did not differ significantly by age or frailty. Post-immunization, IgG increased to all four serotypes; acceptable or strong response ranged between 29% for (6B) and 57% for (18C). There was no significant difference between the two vaccine types (23PPV versus PCV7). At 6 months post-vaccination, the highest geometric mean IgG concentrations (GMCs) were seen for serotype 19F and the lowest for serotype 4. Although there was some variation by serotype, responses after vaccination were lowest in the most frail or aged subjects. Conclusions Pneumococcal vaccines are perceived to offer low protection in the frail elderly, but our study showed that the proportion of this vulnerable population with acceptable responses is encouraging. Frailty, as measured by the Frailty Index, appears to be a better predictor of immune response to pneumococcal vaccines than age alone.
Advanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody responses that increase the risk of invasive pneumococcal disease (IPD) and limit the effectiveness of vaccines. However, the elderly are a heterogeneous group and measures of overall frailty may be a better indicator of disease susceptibility (or vaccine response) than chronological age alone. To evaluate the immunogenicity of the 7-valent conjugated pneumococcal vaccine (PCV7) versus 23-valent polysaccharide vaccine (23vPPV) and compare the immune response to four serotypes (4, 6B, 18C and 19F), with respect to age or frailty in an elderly population of previously unvaccinated hospitalized patients. 241 patients aged 60 years and over, recruited between 16 May 2005 and 20 February 2006, were randomised to 23PPV or PCV7 vaccine. We measured Frailty Index (FI), Barthel index and the MiniMental State. Serotype-specific IgG was measured by ELISA at base line and 6 months after vaccination. Antibody responses were defined by the ratio of post-vaccination to pre-vaccination IgG antibody concentration (poor < 2-fold increase, acceptable ≥ 2.0 to 3.99-fold and strong ≥ 4.0-fold increase). Pre-immunization IgG was generally low and did not differ significantly by age or frailty. Post-immunization, IgG increased to all four serotypes; acceptable or strong response ranged between 29% for (6B) and 57% for (18C). There was no significant difference between the two vaccine types (23PPV versus PCV7). At 6 months post-vaccination, the highest geometric mean IgG concentrations (GMCs) were seen for serotype 19F and the lowest for serotype 4. Although there was some variation by serotype, responses after vaccination were lowest in the most frail or aged subjects. Pneumococcal vaccines are perceived to offer low protection in the frail elderly, but our study showed that the proportion of this vulnerable population with acceptable responses is encouraging. Frailty, as measured by the Frailty Index, appears to be a better predictor of immune response to pneumococcal vaccines than age alone.
Advanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody responses that increase the risk of invasive pneumococcal disease (IPD) and limit the effectiveness of vaccines. However, the elderly are a heterogeneous group and measures of overall frailty may be a better indicator of disease susceptibility (or vaccine response) than chronological age alone. To evaluate the immunogenicity of the 7-valent conjugated pneumococcal vaccine (PCV7) versus 23-valent polysaccharide vaccine (23vPPV) and compare the immune response to four serotypes (4, 6B, 18C and 19F), with respect to age or frailty in an elderly population of previously unvaccinated hospitalized patients. 241 patients aged 60 years and over, recruited between 16 May 2005 and 20 February 2006, were randomised to 23PPV or PCV7 vaccine. We measured Frailty Index (FI), Barthel index and the MiniMental State. Serotype-specific IgG was measured by ELISA at base line and 6 months after vaccination. Antibody responses were defined by the ratio of post-vaccination to pre-vaccination IgG antibody concentration (poor < 2-fold increase, acceptable > or = 2.0 to 3.99-fold and strong > or = 4.0-fold increase). Pre-immunization IgG was generally low and did not differ significantly by age or frailty. Post-immunization, IgG increased to all four serotypes; acceptable or strong response ranged between 29% for (6B) and 57% for (18C). There was no significant difference between the two vaccine types (23PPV versus PCV7). At 6 months post-vaccination, the highest geometric mean IgG concentrations (GMCs) were seen for serotype 19F and the lowest for serotype 4. Although there was some variation by serotype, responses after vaccination were lowest in the most frail or aged subjects. Pneumococcal vaccines are perceived to offer low protection in the frail elderly, but our study showed that the proportion of this vulnerable population with acceptable responses is encouraging. Frailty, as measured by the Frailty Index, appears to be a better predictor of immune response to pneumococcal vaccines than age alone.
Abstract Advanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody responses that increase the risk of invasive pneumococcal disease (IPD) and limit the effectiveness of vaccines. However, the elderly are a heterogeneous group and measures of overall frailty may be a better indicator of disease susceptibility (or vaccine response) than chronological age alone. Aim To evaluate the immunogenicity of the 7-valent conjugated pneumococcal vaccine (PCV7) versus 23-valent polysaccharide vaccine (23vPPV) and compare the immune response to four serotypes (4, 6B, 18C and 19F), with respect to age or frailty in an elderly population of previously unvaccinated hospitalized patients. Method 241 patients aged 60 years and over, recruited between 16 May 2005 and 20 February 2006, were randomised to 23PPV or PCV7 vaccine. We measured Frailty Index (FI), Barthel index and the MiniMental State. Serotype-specific IgG was measured by ELISA at base line and 6 months after vaccination. Antibody responses were defined by the ratio of post-vaccination to pre-vaccination IgG antibody concentration (poor < 2-fold increase, acceptable ≥ 2.0 to 3.99-fold and strong ≥ 4.0-fold increase). Results Pre-immunization IgG was generally low and did not differ significantly by age or frailty. Post-immunization, IgG increased to all four serotypes; acceptable or strong response ranged between 29% for (6B) and 57% for (18C). There was no significant difference between the two vaccine types (23PPV versus PCV7). At 6 months post-vaccination, the highest geometric mean IgG concentrations (GMCs) were seen for serotype 19F and the lowest for serotype 4. Although there was some variation by serotype, responses after vaccination were lowest in the most frail or aged subjects. Conclusions Pneumococcal vaccines are perceived to offer low protection in the frail elderly, but our study showed that the proportion of this vulnerable population with acceptable responses is encouraging. Frailty, as measured by the Frailty Index, appears to be a better predictor of immune response to pneumococcal vaccines than age alone.
Advanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody responses that increase the risk of invasive pneumococcal disease (IPD) and limit the effectiveness of vaccines. However, the elderly are a heterogeneous group and measures of overall frailty may be a better indicator of disease susceptibility (or vaccine response) than chronological age alone.UNLABELLEDAdvanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody responses that increase the risk of invasive pneumococcal disease (IPD) and limit the effectiveness of vaccines. However, the elderly are a heterogeneous group and measures of overall frailty may be a better indicator of disease susceptibility (or vaccine response) than chronological age alone.To evaluate the immunogenicity of the 7-valent conjugated pneumococcal vaccine (PCV7) versus 23-valent polysaccharide vaccine (23vPPV) and compare the immune response to four serotypes (4, 6B, 18C and 19F), with respect to age or frailty in an elderly population of previously unvaccinated hospitalized patients.AIMTo evaluate the immunogenicity of the 7-valent conjugated pneumococcal vaccine (PCV7) versus 23-valent polysaccharide vaccine (23vPPV) and compare the immune response to four serotypes (4, 6B, 18C and 19F), with respect to age or frailty in an elderly population of previously unvaccinated hospitalized patients.241 patients aged 60 years and over, recruited between 16 May 2005 and 20 February 2006, were randomised to 23PPV or PCV7 vaccine. We measured Frailty Index (FI), Barthel index and the MiniMental State. Serotype-specific IgG was measured by ELISA at base line and 6 months after vaccination. Antibody responses were defined by the ratio of post-vaccination to pre-vaccination IgG antibody concentration (poor < 2-fold increase, acceptable > or = 2.0 to 3.99-fold and strong > or = 4.0-fold increase).METHOD241 patients aged 60 years and over, recruited between 16 May 2005 and 20 February 2006, were randomised to 23PPV or PCV7 vaccine. We measured Frailty Index (FI), Barthel index and the MiniMental State. Serotype-specific IgG was measured by ELISA at base line and 6 months after vaccination. Antibody responses were defined by the ratio of post-vaccination to pre-vaccination IgG antibody concentration (poor < 2-fold increase, acceptable > or = 2.0 to 3.99-fold and strong > or = 4.0-fold increase).Pre-immunization IgG was generally low and did not differ significantly by age or frailty. Post-immunization, IgG increased to all four serotypes; acceptable or strong response ranged between 29% for (6B) and 57% for (18C). There was no significant difference between the two vaccine types (23PPV versus PCV7). At 6 months post-vaccination, the highest geometric mean IgG concentrations (GMCs) were seen for serotype 19F and the lowest for serotype 4. Although there was some variation by serotype, responses after vaccination were lowest in the most frail or aged subjects.RESULTSPre-immunization IgG was generally low and did not differ significantly by age or frailty. Post-immunization, IgG increased to all four serotypes; acceptable or strong response ranged between 29% for (6B) and 57% for (18C). There was no significant difference between the two vaccine types (23PPV versus PCV7). At 6 months post-vaccination, the highest geometric mean IgG concentrations (GMCs) were seen for serotype 19F and the lowest for serotype 4. Although there was some variation by serotype, responses after vaccination were lowest in the most frail or aged subjects.Pneumococcal vaccines are perceived to offer low protection in the frail elderly, but our study showed that the proportion of this vulnerable population with acceptable responses is encouraging. Frailty, as measured by the Frailty Index, appears to be a better predictor of immune response to pneumococcal vaccines than age alone.CONCLUSIONSPneumococcal vaccines are perceived to offer low protection in the frail elderly, but our study showed that the proportion of this vulnerable population with acceptable responses is encouraging. Frailty, as measured by the Frailty Index, appears to be a better predictor of immune response to pneumococcal vaccines than age alone.
Author Sullivan, J.S.
MacIntyre, C.R.
Lindley, R.
Ridda, I.
McIntyre, P.B.
Yuan, F.F.
Gao, Z.
Author_xml – sequence: 1
  givenname: I.
  surname: Ridda
  fullname: Ridda, I.
  email: imanridda@hotmail.com
  organization: National Centre for Immunization Research and Surveillance Sydney, NSW, Australia
– sequence: 2
  givenname: C.R.
  surname: MacIntyre
  fullname: MacIntyre, C.R.
  organization: School of Public Health and Community Medicine, The University of New South Wales, Australia
– sequence: 3
  givenname: R.
  surname: Lindley
  fullname: Lindley, R.
  organization: The University of Sydney, Sydney, NSW, Australia
– sequence: 4
  givenname: Z.
  surname: Gao
  fullname: Gao, Z.
  organization: School of Public Health and Community Medicine, The University of New South Wales, Australia
– sequence: 5
  givenname: J.S.
  surname: Sullivan
  fullname: Sullivan, J.S.
  organization: The Australian Red Cross Blood Services, Sydney, NSW, Australia
– sequence: 6
  givenname: F.F.
  surname: Yuan
  fullname: Yuan, F.F.
  organization: The Australian Red Cross Blood Services, Sydney, NSW, Australia
– sequence: 7
  givenname: P.B.
  surname: McIntyre
  fullname: McIntyre, P.B.
  organization: National Centre for Immunization Research and Surveillance Sydney, NSW, Australia
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21289269$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/19100304$$D View this record in MEDLINE/PubMed
BookMark eNqNklFrFDEUhYNU7Lb6E5QB0bdd783sZBJERUrVQsEHFXwL2cwdyTqTTJOZQv-9GXe1sCDrUx7ynZPcc-4ZO_HBE2NPEVYIKF5tV7fGWudpxQHkCnEFSj5gC5R1ueQVyhO2AC7WyzXC91N2ltIWAKoS1SN2igoBSlgv2OVV308-dOGHs6YrIqUh-ESpGEMxeJr6YIOdb_avFc4XbTSuK0LXUCwGCkNHj9nD1nSJnuzPc_btw-XXi0_L688fry7eXy9tJXBccmWMEIq4BODG1qQUkqq5QqwM1OsKGmlQNaIybU1UkuQ1tbWxm0q0GyzLc_Zy5zvEcDNRGnXvkqWuM57ClHQ2r_Jg_CjIoVRVKeoMPj8At2GKPg-hUaCUZSl-U8_21LTpqdFDdL2Jd_pPjhl4sQdMymnlhLx16S_HkUvFhcpcteNsDClFau-tQM-96q3eJ63nXjWizr1m3esDnXWjGV3w41zGUfW7nZpyN7eOok7WkbfUuEh21E1wRx3eHjjYzvl5ZX7SHaX7zHTiGvSXefPmxQOZPWs1B_Tm3wb_8YFfkJDpag
CODEN VACCDE
CitedBy_id crossref_primary_10_1093_cid_cix419
crossref_primary_10_4049_jimmunol_1701065
crossref_primary_10_1093_ageing_afs180
crossref_primary_10_1128_IAI_00653_20
crossref_primary_10_1016_j_idc_2012_11_011
crossref_primary_10_1016_j_jns_2024_123314
crossref_primary_10_1186_s12979_018_0137_4
crossref_primary_10_1016_j_vaccine_2009_10_081
crossref_primary_10_1093_ageing_afac088
crossref_primary_10_1111_j_1532_5415_2009_02667_x
crossref_primary_10_1186_1471_2318_13_64
crossref_primary_10_1111_ajag_12310
crossref_primary_10_1097_IPC_0000000000000455
crossref_primary_10_1586_erv_11_99
crossref_primary_10_1186_s13223_017_0200_2
crossref_primary_10_1016_j_clicom_2022_09_005
crossref_primary_10_1016_j_medmal_2013_04_005
crossref_primary_10_1093_gerona_glt137
crossref_primary_10_1007_s10522_013_9446_3
crossref_primary_10_1016_j_vaccine_2011_02_088
crossref_primary_10_1186_s12979_021_00249_6
crossref_primary_10_4155_cli_13_73
crossref_primary_10_1016_j_idc_2017_07_017
crossref_primary_10_1016_j_bbmt_2019_07_030
crossref_primary_10_1016_S0140_6736_20_32481_8
crossref_primary_10_1089_rej_2010_1078
crossref_primary_10_1097_MD_0b013e3181f2b824
crossref_primary_10_2337_dc20_2664
crossref_primary_10_1016_j_vaccine_2010_03_073
crossref_primary_10_1016_S0140_6736_12_62167_9
crossref_primary_10_1016_j_autrev_2011_05_015
crossref_primary_10_3899_jrheum_130182
crossref_primary_10_3390_vaccines9060589
crossref_primary_10_1111_ggi_70028
crossref_primary_10_4161_hv_8_1_18129
crossref_primary_10_1007_s40273_016_0393_0
crossref_primary_10_1111_jgs_19079
crossref_primary_10_1128_CVI_00408_10
crossref_primary_10_1371_journal_pone_0234698
crossref_primary_10_1136_thoraxjnl_2018_212826
crossref_primary_10_21149_8394
crossref_primary_10_1016_j_arr_2021_101351
crossref_primary_10_1016_j_immuni_2012_10_014
crossref_primary_10_1111_jgs_16917
crossref_primary_10_3928_00989134_20110201_01
crossref_primary_10_1128_CVI_00498_16
crossref_primary_10_1080_21645515_2019_1589282
crossref_primary_10_1186_cc12754
crossref_primary_10_1007_s40266_013_0060_5
crossref_primary_10_1111_jgs_19444
crossref_primary_10_1007_s12603_020_1352_1
crossref_primary_10_1080_21645515_2015_1011954
crossref_primary_10_1016_j_vaccine_2010_04_103
crossref_primary_10_1016_j_arr_2019_100935
crossref_primary_10_1016_j_vaccine_2012_01_015
crossref_primary_10_1016_j_vaccine_2015_08_002
crossref_primary_10_1007_s40520_022_02239_0
crossref_primary_10_1093_gerona_glac214
crossref_primary_10_1177_1098612X18759838
crossref_primary_10_1080_21645515_2018_1438091
crossref_primary_10_1016_j_vaccine_2010_08_004
crossref_primary_10_1016_j_vaccine_2011_06_116
crossref_primary_10_1128_CVI_00007_11
crossref_primary_10_1111_bcp_16034
crossref_primary_10_1093_gerona_glx142
crossref_primary_10_1007_s11904_014_0247_3
crossref_primary_10_1111_j_1532_5415_2009_02480_x
crossref_primary_10_3389_fimmu_2020_00717
crossref_primary_10_3390_vaccines11050908
crossref_primary_10_1586_erp_12_54
crossref_primary_10_1007_s10067_011_1856_5
crossref_primary_10_1586_14760584_2015_963058
crossref_primary_10_3389_fimmu_2018_02465
crossref_primary_10_1371_journal_pone_0259990
crossref_primary_10_1371_journal_pone_0094578
crossref_primary_10_1016_j_vaccine_2016_02_037
crossref_primary_10_3390_vaccines11121780
crossref_primary_10_1016_j_amjmed_2014_05_010
crossref_primary_10_1111_j_1741_6612_2009_00405_x
crossref_primary_10_1371_journal_pone_0082967
crossref_primary_10_1016_j_maturitas_2012_10_010
crossref_primary_10_18632_aging_202572
crossref_primary_10_1016_j_mayocp_2016_01_018
crossref_primary_10_3389_fragi_2021_798868
crossref_primary_10_3109_00365548_2013_867072
crossref_primary_10_1016_j_archger_2010_06_013
crossref_primary_10_1517_14712598_2012_636348
crossref_primary_10_1080_21645515_2015_1098794
crossref_primary_10_1093_gerona_glac077
crossref_primary_10_1186_s12979_017_0098_z
crossref_primary_10_1093_ageing_aft059
crossref_primary_10_1016_j_vaccine_2009_03_075
crossref_primary_10_1080_13814788_2022_2149732
crossref_primary_10_1097_IPC_0000000000000462
crossref_primary_10_1016_j_jamda_2012_05_009
crossref_primary_10_1016_j_vaccine_2017_07_088
crossref_primary_10_3390_v14112361
crossref_primary_10_1093_cid_cis513
crossref_primary_10_1016_j_jcpa_2009_09_009
Cites_doi 10.1097/00007611-198404000-00010
10.1016/S0749-0690(18)30506-8
10.1016/0022-3956(75)90026-6
10.1097/00006454-200003000-00003
10.1111/j.1532-5415.2005.00506.x
10.1056/NEJMoa022678
10.1093/gerona/59.3.M255
10.1055/s-2005-925523
10.1503/cmaj.050051
10.1111/j.1532-5415.2005.53300.x
10.1086/507340
10.1111/j.1532-5415.2004.52521.x
10.1111/j.1365-2648.2006.04021.x
10.1016/j.mad.2006.12.004
10.1086/515644
10.1177/0009922807301484
10.1080/09638280500215867
10.4161/hv.3.3.3925
10.1111/j.1532-5415.2005.53312.x
10.1016/S0091-6749(96)70244-0
10.1016/j.ophtha.2006.04.035
10.1093/infdis/149.6.861
10.1017/S1462399407000221
10.1007/s00431-001-0907-3
10.1016/j.mad.2004.05.003
10.1093/gerona/57.5.M283
10.1111/j.1532-5415.2006.00738.x
10.1128/CDLI.10.4.514-519.2003
10.1086/520200
10.1128/CMR.16.2.308-318.2003
10.3138/8774-758W-702Q-2531
10.1016/j.vaccine.2007.02.062
10.1159/000094009
10.1016/S0264-410X(99)00122-X
10.1177/147323000503300503
10.1093/gerona/60.8.1046
ContentType Journal Article
Copyright 2008 Elsevier Ltd
Elsevier Ltd
2009 INIST-CNRS
Copyright Elsevier Limited Mar 4, 2009
Copyright_xml – notice: 2008 Elsevier Ltd
– notice: Elsevier Ltd
– notice: 2009 INIST-CNRS
– notice: Copyright Elsevier Limited Mar 4, 2009
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7RV
7T2
7T5
7U9
7X7
7XB
88C
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
GUQSH
H94
HCIFZ
K9-
K9.
KB0
LK8
M0R
M0S
M0T
M1P
M2O
M7N
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
DOI 10.1016/j.vaccine.2008.11.098
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Nursing & Allied Health Database
Health and Safety Science Abstracts (Full archive)
Immunology Abstracts
Virology and AIDS Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Healthcare Administration Database (Alumni)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
AIDS and Cancer Research Abstracts
SciTech Premium Collection
Consumer Health Database (Alumni Edition)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Biological Science Collection
Family Health Database
ProQuest Health & Medical Collection
Healthcare Administration Database
PML(ProQuest Medical Library)
Research Library
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Research Library Prep
ProQuest Central Student
ProQuest Central Essentials
SciTech Premium Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest Family Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest Health Management (Alumni Edition)
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Family Health (Alumni Edition)
ProQuest Central
ProQuest Health & Medical Research Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
AIDS and Cancer Research Abstracts
ProQuest Research Library
Health & Safety Science Abstracts
ProQuest Public Health
ProQuest Central Basic
ProQuest Health Management
ProQuest Nursing & Allied Health Source
ProQuest SciTech Collection
ProQuest Medical Library
Immunology Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Research Library Prep

AIDS and Cancer Research Abstracts
MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Veterinary Medicine
Biology
Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-2518
EndPage 1636
ExternalDocumentID 3476786571
19100304
21289269
10_1016_j_vaccine_2008_11_098
S0264410X08016794
1_s2_0_S0264410X08016794
Genre Randomized Controlled Trial
Journal Article
Comparative Study
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
29Q
4.4
457
4G.
53G
5RE
5VS
7-5
71M
7RV
7X7
88E
8AO
8C1
8FE
8FH
8FI
8FJ
8G5
8P~
9JM
AAAJQ
AABNK
AAEDT
AAEDW
AAHBH
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABJNI
ABKYH
ABMAC
ABMZM
ABRWV
ABUWG
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACIUM
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFRT
ADMUD
ADNMO
ADVLN
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEUYN
AEVXI
AEXOQ
AFJKZ
AFKRA
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGEKW
AGGSO
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AHMBA
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
AQUVI
ASPBG
AVWKF
AXJTR
AZFZN
AZQEC
BBNVY
BENPR
BHPHI
BKEYQ
BKNYI
BKOJK
BLXMC
BNPGV
BPHCQ
BVXVI
CCPQU
CJTIS
CNWQP
CS3
DWQXO
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-2
G-Q
GBLVA
GNUQQ
GUQSH
HCIFZ
HEJ
HLV
HMCUK
HMG
HMK
HMO
HVGLF
HX~
HZ~
IHE
J1W
K9-
KOM
L7B
LK8
LUGTX
LW9
M0R
M0T
M1P
M29
M2O
M41
M7P
MO0
N9A
NAPCQ
O-L
O9-
O9~
OAUVE
OK0
OZT
P-8
P-9
P2P
PC.
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PUEGO
Q38
R2-
ROL
RPZ
SAB
SAE
SCC
SDF
SDG
SDP
SES
SEW
SIN
SNL
SPCBC
SSH
SSI
SSZ
SVS
T5K
UKHRP
UV1
WH7
WOW
WUQ
XPP
Z5R
ZGI
ZXP
~G-
3V.
AACTN
AFCTW
AFKWA
AJOXV
ALIPV
AMFUW
RIG
AAIAV
ABLVK
ABYKQ
AESVU
AJBFU
EFLBG
LCYCR
QYZTP
AAYXX
ACMHX
ADSLC
AGRNS
AGWPP
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7T2
7T5
7U9
7XB
8FK
C1K
H94
K9.
M7N
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
ID FETCH-LOGICAL-c561t-29aa669e28002ac7e991e9729115a07450d8a19d65af7ee3e827ef7acb56fb133
IEDL.DBID 7X7
ISSN 0264-410X
IngestDate Fri Jul 11 05:00:36 EDT 2025
Fri Jul 11 05:42:06 EDT 2025
Wed Aug 13 02:37:47 EDT 2025
Mon Jul 21 05:47:04 EDT 2025
Mon Jul 21 09:14:21 EDT 2025
Tue Jul 01 03:37:38 EDT 2025
Thu Apr 24 23:10:55 EDT 2025
Fri Feb 23 02:28:42 EST 2024
Sun Feb 23 10:19:14 EST 2025
Tue Aug 26 17:02:19 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords Pneumococcal vaccines
Pneumococcal disease
Immune responses
Older people
Frail
Human
Immune response
Vaccine
Streptococcus pneumoniae
Infection
Streptococcaceae
Streptococcal infection
Bacteriosis
Bacteria
Micrococcales
Elderly
Pneumococcal infection
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c561t-29aa669e28002ac7e991e9729115a07450d8a19d65af7ee3e827ef7acb56fb133
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ObjectType-Undefined-3
PMID 19100304
PQID 1618833667
PQPubID 105530
PageCount 9
ParticipantIDs proquest_miscellaneous_66950032
proquest_miscellaneous_20395367
proquest_journals_1618833667
pubmed_primary_19100304
pascalfrancis_primary_21289269
crossref_primary_10_1016_j_vaccine_2008_11_098
crossref_citationtrail_10_1016_j_vaccine_2008_11_098
elsevier_sciencedirect_doi_10_1016_j_vaccine_2008_11_098
elsevier_clinicalkeyesjournals_1_s2_0_S0264410X08016794
elsevier_clinicalkey_doi_10_1016_j_vaccine_2008_11_098
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2009-03-04
PublicationDateYYYYMMDD 2009-03-04
PublicationDate_xml – month: 03
  year: 2009
  text: 2009-03-04
  day: 04
PublicationDecade 2000
PublicationPlace Kidlington
PublicationPlace_xml – name: Kidlington
– name: Netherlands
PublicationTitle Vaccine
PublicationTitleAlternate Vaccine
PublicationYear 2009
Publisher Elsevier Ltd
Elsevier
Elsevier Limited
Publisher_xml – name: Elsevier Ltd
– name: Elsevier
– name: Elsevier Limited
References Rockwood, Song, MacKnight, Berman, Hogan, McDowell (bib19) 2005; 173
Rubins, Puri, Loch (bib36) 1998; 178
Fried, Ferrucci, Darer, Williamson, Anderson (bib16) 2004; 59
Martinsson, Eksborg (bib27) 2006; 22
Rockwood, Mitnitski, Song, Steen, Skoog (bib23) 2006; 54
Rockwood (bib18) 2005; 53
Blaum, Xue, Michelon, Semba, Fried (bib21) 2005; 53
Douglas, Miles (bib9) 1984; 149
Kovaiou, Herndler-Brandstetter, Grubeck-Loebenstein (bib5) 2007; 9
Cartwright (bib4) 2002; 161
Klein, Klein, Knudtson (bib22) 2006; 113
Woo, Goggins, Sham, Ho (bib41) 2006; 28
Goggins, Woo, Sham, Ho (bib40) 2005; 60
The Department of Infrastructure Planning and Natural Resources. Health service profile. Population projection for SWAHS. Annual report. NSW Government. Accessed 2005.
Bortz (bib15) 2002; 57
Mitnitski, Song, Skoog, Broe, Cox, Grunfeld (bib25) 2005; 53
Karma, Luotonen, Timonen, Pontynen, Pukander, Herva (bib10) 1980; 89
Pneumococcal antibody testing. IBT Laboratories; 2008 [cited April 28, 2008].
Australian Bureau of Statistics. Population Projections Australia 2002–2100;2003.
Rockwood, Mogilner, Mitnitski (bib24) 2004; 125
Folstein, Folstein, McHugh (bib28) 1975; 12
(bib2) 1977; 46
Jackson, Neuzil, Nahm, Whitney, Yu, Nelson (bib12) 2007; 25
Ansaldi, Turello, Lai, Bastone, De Luca, Rosselli (bib8) 2005; 33
Wernette, Frasch, Madore (bib30) 2003; 10
Fedson (bib39) 1992; 8
Ortqvist, Hedlund, Kalin (bib13) 2005; 26
Black, Shinefield, Fireman, Lewis, Ray, Hansen (bib11) 2000; 19
Berk, Verghese, Berk, Dison, Smith (bib37) 1984; 77
Romero-Steiner, Musher, Cetron (bib35) 1999; 29
Anonymous (bib29) 2003
Boom, Nelson, Laufman, Kohrt, Kozinetz (bib38) 2007; 46
Jones, Song, Rockwood (bib42) 2004; 52
Go, Ballas (bib32) 1996; 98
Ridda, MacIntyre, Lindley, McIntyre, Sullivan, Gilbert (bib34) 2007; 3
Levers, Estabrooks, Ross Kerr (bib17) 2006 Nov; 56
Jackson, Neuzil, Yu, Benson, Barlow, Adams (bib6) 2003; 348
Andrew, Rockwood (bib20) 2007; 26
Fedson, Scott (bib3) 1999
Vila-Corcoles, Ochoa-Gondar, Hospital, Ansa, Vilanova, Rodriquez (bib7) 2006; 43
Artz, Ershler, Longo (bib14) 2003; 16
Kulminski, Yashin, Arbeev, Akushevich, Ukraintseva, Land (bib43) 2007; 128
Anonymous. CDC ELISA Program. Centers for Disease Control 2003; Vol. 2004.
10.1016/j.vaccine.2008.11.098_bib33
Karma (10.1016/j.vaccine.2008.11.098_bib10) 1980; 89
Ridda (10.1016/j.vaccine.2008.11.098_bib34) 2007; 3
10.1016/j.vaccine.2008.11.098_bib31
Boom (10.1016/j.vaccine.2008.11.098_bib38) 2007; 46
Berk (10.1016/j.vaccine.2008.11.098_bib37) 1984; 77
Woo (10.1016/j.vaccine.2008.11.098_bib41) 2006; 28
Kovaiou (10.1016/j.vaccine.2008.11.098_bib5) 2007; 9
Bortz (10.1016/j.vaccine.2008.11.098_bib15) 2002; 57
Klein (10.1016/j.vaccine.2008.11.098_bib22) 2006; 113
Ortqvist (10.1016/j.vaccine.2008.11.098_bib13) 2005; 26
Martinsson (10.1016/j.vaccine.2008.11.098_bib27) 2006; 22
Douglas (10.1016/j.vaccine.2008.11.098_bib9) 1984; 149
Artz (10.1016/j.vaccine.2008.11.098_bib14) 2003; 16
Rockwood (10.1016/j.vaccine.2008.11.098_bib19) 2005; 173
Mitnitski (10.1016/j.vaccine.2008.11.098_bib25) 2005; 53
10.1016/j.vaccine.2008.11.098_bib1
Rockwood (10.1016/j.vaccine.2008.11.098_bib23) 2006; 54
Rubins (10.1016/j.vaccine.2008.11.098_bib36) 1998; 178
(10.1016/j.vaccine.2008.11.098_bib2) 1977; 46
Black (10.1016/j.vaccine.2008.11.098_bib11) 2000; 19
Anonymous (10.1016/j.vaccine.2008.11.098_bib29) 2003
Rockwood (10.1016/j.vaccine.2008.11.098_bib24) 2004; 125
Jones (10.1016/j.vaccine.2008.11.098_bib42) 2004; 52
Vila-Corcoles (10.1016/j.vaccine.2008.11.098_bib7) 2006; 43
Wernette (10.1016/j.vaccine.2008.11.098_bib30) 2003; 10
Jackson (10.1016/j.vaccine.2008.11.098_bib12) 2007; 25
Go (10.1016/j.vaccine.2008.11.098_bib32) 1996; 98
Kulminski (10.1016/j.vaccine.2008.11.098_bib43) 2007; 128
Fried (10.1016/j.vaccine.2008.11.098_bib16) 2004; 59
Romero-Steiner (10.1016/j.vaccine.2008.11.098_bib35) 1999; 29
Blaum (10.1016/j.vaccine.2008.11.098_bib21) 2005; 53
Ansaldi (10.1016/j.vaccine.2008.11.098_bib8) 2005; 33
Folstein (10.1016/j.vaccine.2008.11.098_bib28) 1975; 12
Levers (10.1016/j.vaccine.2008.11.098_bib17) 2006; 56
Rockwood (10.1016/j.vaccine.2008.11.098_bib18) 2005; 53
Andrew (10.1016/j.vaccine.2008.11.098_bib20) 2007; 26
Fedson (10.1016/j.vaccine.2008.11.098_bib39) 1992; 8
Cartwright (10.1016/j.vaccine.2008.11.098_bib4) 2002; 161
Goggins (10.1016/j.vaccine.2008.11.098_bib40) 2005; 60
Fedson (10.1016/j.vaccine.2008.11.098_bib3) 1999
Jackson (10.1016/j.vaccine.2008.11.098_bib6) 2003; 348
10.1016/j.vaccine.2008.11.098_bib26
Vaccine. 2009 Nov 5;27(47):6649
References_xml – year: 2003
  ident: bib29
  article-title: Bacterial respiratory pathogen
– volume: 59
  start-page: 255
  year: 2004
  end-page: 263
  ident: bib16
  article-title: Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care
  publication-title: J Gerontol A: Biol Sci Med Sci
– reference: Pneumococcal antibody testing. IBT Laboratories; 2008 [cited April 28, 2008].
– volume: 26
  start-page: 33
  year: 2007
  end-page: 38
  ident: bib20
  article-title: Psychiatric illness in relation to frailty in community-dwelling elderly people without dementia: a report from the Canadian study of health and aging
  publication-title: Can J Aging
– reference: The Department of Infrastructure Planning and Natural Resources. Health service profile. Population projection for SWAHS. Annual report. NSW Government. Accessed 2005.
– volume: 46
  start-page: 1
  year: 1977
  end-page: 24
  ident: bib2
  article-title: Prevention of pneumococcal disease
  publication-title: MMWR
– volume: 56
  start-page: 282
  year: 2006 Nov
  end-page: 291
  ident: bib17
  article-title: Factors contributing to frailty: literature review
  publication-title: J Adv Nurs
– volume: 128
  start-page: 250
  year: 2007
  end-page: 258
  ident: bib43
  article-title: Cumulative index of health disorders as an indicator of aging-associated processes in the elderly: results from analyses of the National Long Term Care Survey
  publication-title: Mech Ageing Dev
– volume: 178
  start-page: 431
  year: 1998
  end-page: 440
  ident: bib36
  article-title: Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults
  publication-title: J Infect Dis
– volume: 28
  start-page: 515
  year: 2006
  end-page: 521
  ident: bib41
  article-title: Public health significance of the frailty index
  publication-title: Disabil Rehabil
– volume: 33
  start-page: 490
  year: 2005
  end-page: 500
  ident: bib8
  article-title: Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study
  publication-title: J Int Med Res
– volume: 53
  start-page: 1069
  year: 2005
  end-page: 1070
  ident: bib18
  article-title: Frailty and its definition: a worthy challenge
  publication-title: J Am Geriatr Soc
– volume: 125
  start-page: 517
  year: 2004
  end-page: 519
  ident: bib24
  article-title: Changes with age in the distribution of a frailty index
  publication-title: Mech Ageing Dev
– volume: 52
  start-page: 1929
  year: 2004
  end-page: 1933
  ident: bib42
  article-title: Operationalizing a frailty index from a standardized comprehensive geriatric assessment
  publication-title: J Am Geriatr Soc
– volume: 60
  start-page: 1046
  year: 2005
  end-page: 1051
  ident: bib40
  article-title: Frailty index as a measure of biological age in a Chinese population
  publication-title: J Gerontol A: Biol Sci Med Sci
– volume: 53
  start-page: 2184
  year: 2005
  end-page: 2189
  ident: bib25
  article-title: Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality
  publication-title: J Am Geriatr Soc
– volume: 10
  start-page: 514
  year: 2003
  end-page: 519
  ident: bib30
  article-title: Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides
  publication-title: Clin Diagn Lab Immunol
– volume: 46
  start-page: 706
  year: 2007
  end-page: 717
  ident: bib38
  article-title: Improvement in provider immunization knowledge and behaviors following a peer education intervention
  publication-title: Clin Pediatr
– volume: 149
  start-page: 861
  year: 1984
  end-page: 869
  ident: bib9
  article-title: Vaccination against streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children
  publication-title: J Infect Dis
– volume: 12
  start-page: 189
  year: 1975
  end-page: 198
  ident: bib28
  article-title: “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician
  publication-title: J Psychiatr Res
– volume: 98
  start-page: 205
  year: 1996
  end-page: 215
  ident: bib32
  article-title: Anti-pneumococcal antibody response in normal subjects: a meta-analysis
  publication-title: J Allergy Clin Immunol
– volume: 43
  start-page: 860
  year: 2006
  end-page: 868
  ident: bib7
  article-title: Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study
  publication-title: Clin Infect Dis
– volume: 8
  start-page: 183
  year: 1992
  end-page: 199
  ident: bib39
  article-title: Clinical practice and public policy for influenza and pneumococcal vaccination of the elderly
  publication-title: Clin Geriatr Med
– volume: 3
  start-page: 83
  year: 2007
  end-page: 86
  ident: bib34
  article-title: Predictors of pneumococcal vaccination uptake in hospitalized patients aged 65 years and over shortly following the commencement of a publicly funded national pneumococcal vaccination program in Australia
  publication-title: Hum Vaccin
– volume: 26
  start-page: 563
  year: 2005
  end-page: 574
  ident: bib13
  article-title: Streptococcus pneumoniae: epidemiology, risk factors, and clinical features
  publication-title: Semin Resp Crit Care Med
– volume: 77
  start-page: 450
  year: 1984
  end-page: 454
  ident: bib37
  article-title: Survey of physician acceptance of the pneumococcal vaccine
  publication-title: South Med J
– volume: 161
  start-page: 188
  year: 2002
  end-page: 195
  ident: bib4
  article-title: Pneumococcal disease in Western Europe: burden of disease, antibiotic resistance and management
  publication-title: Eur J Pediatr
– reference: Anonymous. CDC ELISA Program. Centers for Disease Control 2003; Vol. 2004.
– volume: 348
  start-page: 1747
  year: 2003
  end-page: 1755
  ident: bib6
  article-title: Effectiveness of pneumococcal polysaccharide vaccine in older adults
  publication-title: N Engl J Med
– volume: 173
  start-page: 489
  year: 2005
  end-page: 495
  ident: bib19
  article-title: A global clinical measure of fitness and frailty in elderly people
  publication-title: CMAJ
– volume: 54
  start-page: 975
  year: 2006
  end-page: 979
  ident: bib23
  article-title: Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70
  publication-title: J Am Geriatr Soc
– volume: 25
  start-page: 4029
  year: 2007
  end-page: 4037
  ident: bib12
  article-title: Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
  publication-title: Vaccine
– volume: 22
  start-page: 231
  year: 2006
  end-page: 239
  ident: bib27
  article-title: Activity Index—a complementary ADL scale to the Barthel Index in the acute stage in patients with severe stroke
  publication-title: Cerebrovasc Dis
– start-page: S11
  year: 1999
  end-page: S18
  ident: bib3
  article-title: The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known
  publication-title: Vaccine
– reference: Australian Bureau of Statistics. Population Projections Australia 2002–2100;2003.
– volume: 113
  start-page: 2209
  year: 2006
  end-page: 2212
  ident: bib22
  article-title: Frailty and age-related cataract
  publication-title: Ophthalmology
– volume: 57
  start-page: M283
  year: 2002
  end-page: M288
  ident: bib15
  article-title: A conceptual framework of frailty: a review
  publication-title: J Gerontol A: Biol Sci Med Sci
– volume: 89
  year: 1980
  ident: bib10
  article-title: Efficacy of pneumococcal vaccination against recurrent otitis media. Preliminary results of a field trial in Finland
  publication-title: Ann Otol Rhinol Laryngol
– volume: 19
  start-page: 187
  year: 2000
  end-page: 195
  ident: bib11
  article-title: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
  publication-title: Pediatr Infect Dis J
– volume: 9
  start-page: 1
  year: 2007
  end-page: 17
  ident: bib5
  article-title: Age-related changes in immunity: implications for vaccination in the elderly
  publication-title: Expert Rev Mol Med
– volume: 16
  start-page: 308
  year: 2003
  end-page: 318
  ident: bib14
  article-title: Pneumococcal vaccination and revaccination of older adults
  publication-title: Clin Microbiol Rev
– volume: 53
  start-page: 927
  year: 2005
  end-page: 934
  ident: bib21
  article-title: The association between obesity and the frailty syndrome in older women: the women's health and aging studies
  publication-title: J Am Geriatr Soc
– volume: 29
  start-page: 281
  year: 1999
  end-page: 288
  ident: bib35
  article-title: Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity
  publication-title: Clin Infect Dis
– volume: 77
  start-page: 450
  issue: April (4)
  year: 1984
  ident: 10.1016/j.vaccine.2008.11.098_bib37
  article-title: Survey of physician acceptance of the pneumococcal vaccine
  publication-title: South Med J
  doi: 10.1097/00007611-198404000-00010
– volume: 8
  start-page: 183
  issue: 1
  year: 1992
  ident: 10.1016/j.vaccine.2008.11.098_bib39
  article-title: Clinical practice and public policy for influenza and pneumococcal vaccination of the elderly
  publication-title: Clin Geriatr Med
  doi: 10.1016/S0749-0690(18)30506-8
– volume: 12
  start-page: 189
  issue: November (3)
  year: 1975
  ident: 10.1016/j.vaccine.2008.11.098_bib28
  article-title: “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician
  publication-title: J Psychiatr Res
  doi: 10.1016/0022-3956(75)90026-6
– ident: 10.1016/j.vaccine.2008.11.098_bib33
– volume: 19
  start-page: 187
  issue: 3
  year: 2000
  ident: 10.1016/j.vaccine.2008.11.098_bib11
  article-title: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
  publication-title: Pediatr Infect Dis J
  doi: 10.1097/00006454-200003000-00003
– volume: 53
  start-page: 2184
  issue: December (12)
  year: 2005
  ident: 10.1016/j.vaccine.2008.11.098_bib25
  article-title: Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.2005.00506.x
– ident: 10.1016/j.vaccine.2008.11.098_bib31
– volume: 348
  start-page: 1747
  issue: May (18)
  year: 2003
  ident: 10.1016/j.vaccine.2008.11.098_bib6
  article-title: Effectiveness of pneumococcal polysaccharide vaccine in older adults
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa022678
– volume: 59
  start-page: 255
  issue: March (3)
  year: 2004
  ident: 10.1016/j.vaccine.2008.11.098_bib16
  article-title: Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care
  publication-title: J Gerontol A: Biol Sci Med Sci
  doi: 10.1093/gerona/59.3.M255
– ident: 10.1016/j.vaccine.2008.11.098_bib26
– volume: 26
  start-page: 563
  issue: December (6)
  year: 2005
  ident: 10.1016/j.vaccine.2008.11.098_bib13
  article-title: Streptococcus pneumoniae: epidemiology, risk factors, and clinical features
  publication-title: Semin Resp Crit Care Med
  doi: 10.1055/s-2005-925523
– ident: 10.1016/j.vaccine.2008.11.098_bib1
– volume: 173
  start-page: 489
  issue: August (5)
  year: 2005
  ident: 10.1016/j.vaccine.2008.11.098_bib19
  article-title: A global clinical measure of fitness and frailty in elderly people
  publication-title: CMAJ
  doi: 10.1503/cmaj.050051
– volume: 53
  start-page: 927
  issue: June (6)
  year: 2005
  ident: 10.1016/j.vaccine.2008.11.098_bib21
  article-title: The association between obesity and the frailty syndrome in older women: the women's health and aging studies
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.2005.53300.x
– volume: 43
  start-page: 860
  issue: 7
  year: 2006
  ident: 10.1016/j.vaccine.2008.11.098_bib7
  article-title: Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study
  publication-title: Clin Infect Dis
  doi: 10.1086/507340
– volume: 52
  start-page: 1929
  issue: 11
  year: 2004
  ident: 10.1016/j.vaccine.2008.11.098_bib42
  article-title: Operationalizing a frailty index from a standardized comprehensive geriatric assessment
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.2004.52521.x
– volume: 56
  start-page: 282
  issue: November (3)
  year: 2006
  ident: 10.1016/j.vaccine.2008.11.098_bib17
  article-title: Factors contributing to frailty: literature review
  publication-title: J Adv Nurs
  doi: 10.1111/j.1365-2648.2006.04021.x
– year: 2003
  ident: 10.1016/j.vaccine.2008.11.098_bib29
– volume: 128
  start-page: 250
  issue: March (3)
  year: 2007
  ident: 10.1016/j.vaccine.2008.11.098_bib43
  article-title: Cumulative index of health disorders as an indicator of aging-associated processes in the elderly: results from analyses of the National Long Term Care Survey
  publication-title: Mech Ageing Dev
  doi: 10.1016/j.mad.2006.12.004
– volume: 178
  start-page: 431
  issue: 2
  year: 1998
  ident: 10.1016/j.vaccine.2008.11.098_bib36
  article-title: Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults
  publication-title: J Infect Dis
  doi: 10.1086/515644
– volume: 46
  start-page: 706
  year: 2007
  ident: 10.1016/j.vaccine.2008.11.098_bib38
  article-title: Improvement in provider immunization knowledge and behaviors following a peer education intervention
  publication-title: Clin Pediatr
  doi: 10.1177/0009922807301484
– volume: 28
  start-page: 515
  issue: 8
  year: 2006
  ident: 10.1016/j.vaccine.2008.11.098_bib41
  article-title: Public health significance of the frailty index
  publication-title: Disabil Rehabil
  doi: 10.1080/09638280500215867
– volume: 3
  start-page: 83
  issue: 3
  year: 2007
  ident: 10.1016/j.vaccine.2008.11.098_bib34
  article-title: Predictors of pneumococcal vaccination uptake in hospitalized patients aged 65 years and over shortly following the commencement of a publicly funded national pneumococcal vaccination program in Australia
  publication-title: Hum Vaccin
  doi: 10.4161/hv.3.3.3925
– volume: 53
  start-page: 1069
  issue: June (6)
  year: 2005
  ident: 10.1016/j.vaccine.2008.11.098_bib18
  article-title: Frailty and its definition: a worthy challenge
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.2005.53312.x
– volume: 98
  start-page: 205
  issue: 1
  year: 1996
  ident: 10.1016/j.vaccine.2008.11.098_bib32
  article-title: Anti-pneumococcal antibody response in normal subjects: a meta-analysis
  publication-title: J Allergy Clin Immunol
  doi: 10.1016/S0091-6749(96)70244-0
– volume: 46
  start-page: 1
  year: 1977
  ident: 10.1016/j.vaccine.2008.11.098_bib2
  article-title: Prevention of pneumococcal disease
  publication-title: MMWR
– volume: 89
  issue: May (3:Pt 2)
  year: 1980
  ident: 10.1016/j.vaccine.2008.11.098_bib10
  article-title: Efficacy of pneumococcal vaccination against recurrent otitis media. Preliminary results of a field trial in Finland
  publication-title: Ann Otol Rhinol Laryngol
– volume: 113
  start-page: 2209
  issue: December (12)
  year: 2006
  ident: 10.1016/j.vaccine.2008.11.098_bib22
  article-title: Frailty and age-related cataract
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2006.04.035
– volume: 149
  start-page: 861
  issue: 6
  year: 1984
  ident: 10.1016/j.vaccine.2008.11.098_bib9
  article-title: Vaccination against streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children
  publication-title: J Infect Dis
  doi: 10.1093/infdis/149.6.861
– volume: 9
  start-page: 1
  issue: 3
  year: 2007
  ident: 10.1016/j.vaccine.2008.11.098_bib5
  article-title: Age-related changes in immunity: implications for vaccination in the elderly
  publication-title: Expert Rev Mol Med
  doi: 10.1017/S1462399407000221
– volume: 161
  start-page: 188
  issue: April (4)
  year: 2002
  ident: 10.1016/j.vaccine.2008.11.098_bib4
  article-title: Pneumococcal disease in Western Europe: burden of disease, antibiotic resistance and management
  publication-title: Eur J Pediatr
  doi: 10.1007/s00431-001-0907-3
– volume: 125
  start-page: 517
  issue: July (7)
  year: 2004
  ident: 10.1016/j.vaccine.2008.11.098_bib24
  article-title: Changes with age in the distribution of a frailty index
  publication-title: Mech Ageing Dev
  doi: 10.1016/j.mad.2004.05.003
– volume: 57
  start-page: M283
  issue: May (5)
  year: 2002
  ident: 10.1016/j.vaccine.2008.11.098_bib15
  article-title: A conceptual framework of frailty: a review
  publication-title: J Gerontol A: Biol Sci Med Sci
  doi: 10.1093/gerona/57.5.M283
– volume: 54
  start-page: 975
  issue: June (6)
  year: 2006
  ident: 10.1016/j.vaccine.2008.11.098_bib23
  article-title: Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70
  publication-title: J Am Geriatr Soc
  doi: 10.1111/j.1532-5415.2006.00738.x
– volume: 10
  start-page: 514
  issue: July (4)
  year: 2003
  ident: 10.1016/j.vaccine.2008.11.098_bib30
  article-title: Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides
  publication-title: Clin Diagn Lab Immunol
  doi: 10.1128/CDLI.10.4.514-519.2003
– volume: 29
  start-page: 281
  issue: 2
  year: 1999
  ident: 10.1016/j.vaccine.2008.11.098_bib35
  article-title: Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity
  publication-title: Clin Infect Dis
  doi: 10.1086/520200
– volume: 16
  start-page: 308
  issue: April (2)
  year: 2003
  ident: 10.1016/j.vaccine.2008.11.098_bib14
  article-title: Pneumococcal vaccination and revaccination of older adults
  publication-title: Clin Microbiol Rev
  doi: 10.1128/CMR.16.2.308-318.2003
– volume: 26
  start-page: 33
  issue: 1
  year: 2007
  ident: 10.1016/j.vaccine.2008.11.098_bib20
  article-title: Psychiatric illness in relation to frailty in community-dwelling elderly people without dementia: a report from the Canadian study of health and aging
  publication-title: Can J Aging
  doi: 10.3138/8774-758W-702Q-2531
– volume: 25
  start-page: 4029
  issue: May (20)
  year: 2007
  ident: 10.1016/j.vaccine.2008.11.098_bib12
  article-title: Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2007.02.062
– volume: 22
  start-page: 231
  issue: 4
  year: 2006
  ident: 10.1016/j.vaccine.2008.11.098_bib27
  article-title: Activity Index—a complementary ADL scale to the Barthel Index in the acute stage in patients with severe stroke
  publication-title: Cerebrovasc Dis
  doi: 10.1159/000094009
– start-page: S11
  issue: 17
  year: 1999
  ident: 10.1016/j.vaccine.2008.11.098_bib3
  article-title: The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known
  publication-title: Vaccine
  doi: 10.1016/S0264-410X(99)00122-X
– volume: 33
  start-page: 490
  issue: Sep (5)
  year: 2005
  ident: 10.1016/j.vaccine.2008.11.098_bib8
  article-title: Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study
  publication-title: J Int Med Res
  doi: 10.1177/147323000503300503
– volume: 60
  start-page: 1046
  issue: August (8)
  year: 2005
  ident: 10.1016/j.vaccine.2008.11.098_bib40
  article-title: Frailty index as a measure of biological age in a Chinese population
  publication-title: J Gerontol A: Biol Sci Med Sci
  doi: 10.1093/gerona/60.8.1046
– reference: - Vaccine. 2009 Nov 5;27(47):6649
SSID ssj0005319
Score 2.3035636
Snippet Advanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody responses...
Abstract Advanced age has been associated with a wide range of defects in both the innate and adaptive immune systems including diminished specific antibody...
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1628
SubjectTerms Aged
Aged, 80 and over
Allergy and Immunology
Antibodies, Bacterial - blood
Applied microbiology
Bacterial diseases
Bacteriology
Biological and medical sciences
Female
Frail
Frail Elderly
Frailty
Fundamental and applied biological sciences. Psychology
Heptavalent Pneumococcal Conjugate Vaccine
Human bacterial diseases
Humans
Immune response
Immune responses
Immunization
Immunogenicity
Immunoglobulin G - blood
Infectious diseases
Male
Medical sciences
Microbiology
Middle Aged
Miscellaneous
Older people
Pneumococcal disease
Pneumococcal Infections - immunology
Pneumococcal Infections - prevention & control
Pneumococcal vaccines
Pneumococcal Vaccines - immunology
Pneumococcal Vaccines - pharmacology
Pneumonia
Staphylococcal infections, streptococcal infections, pneumococcal infections
Streptococcus pneumoniae
Streptococcus pneumoniae - classification
Streptococcus pneumoniae - immunology
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
SummonAdditionalLinks – databaseName: Elsevier SD Freedom Collection Journals [SCFCJ]
  dbid: AIKHN
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEB9qiyKI6PkVrXUfpE9NL9kkm-xjKS1XpaVgK_e2bPY2cKUmR3Mn9L93Jru5ULRWfM1mSGZ2duaXzBfA5zKaZZnNeMiT0oRpKU2o0bOEVV6JnEczE5f0Q__0TEwu0y_TbLoBh30tDKVVetvvbHpnrf2VsZfmeDGfj79FnS-Ppoh5KJaQPoItnkiBqr11cPJ1cjZkeiTdfA-6PySCoZBnfLX_UxuKYLusSurnKYv7XNSzhW5RcJWbeHE_JO1c0_ELeO4xJTtwr_0SNmw9gsduyuTtCJ6c-vj5CHbPXafq2z12MRRetXtsl50PPayRZvSd0mS6Wl3Wk7-CoxOqJunNJbtx-bW2ZcuGLWq7-tGgeaUVzy6b1wz5mF-zhoaBM5eu_houj48uDiehn8MQGkRXy5BLrYWQlhO41Ca3iCmtRFSOaFIjBMmiWaFjOROZrnJrE1vw3Fa5NmUmqhI_gt_AZt3U9h0wBCtxaahpHRW5Jqku0zw1XJoo43pW2ADSXvTK-CblNCvjWvXZaFfKs-AGaOLnC-5YAPtrsoXr0vEQgej3VfUlqGg0FfqRhwjzPxHa1h_9VsWq5SpSv6lnAMWa8o6G_8tDd-6o3ppHxB2F5EIGsN3rohpeRMQ0SVqIPIBP62W0HhQS0rVtVi0-JKH4_V_uwI3P0PLzAN46HR8EjEiTAuvv_5-xD_DUReeSMEq3YXN5s7IfEeQtyx1_iH8BKIBPVA
  priority: 102
  providerName: Elsevier
Title Immunological responses to pneumococcal vaccine in frail older people
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X08016794
https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X08016794
https://dx.doi.org/10.1016/j.vaccine.2008.11.098
https://www.ncbi.nlm.nih.gov/pubmed/19100304
https://www.proquest.com/docview/1618833667
https://www.proquest.com/docview/20395367
https://www.proquest.com/docview/66950032
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9RAFD7YFkUooqvVaF3nQfrUbJPJZZInqWXLVumyaCv7FiaTCbTUZNvsCn3xt3tOZrJBsK0vSSA5TOZ25ps5lw_gY-4VUaQj7vIgV26Yp8qVuLK4pShjwb1C-Tkd6J9O48l5-GUeze2BW2PdKjud2CrqolZ0Rn5Aid2TIIhj8Wlx7RJrFFlXLYXGBmxR6jJy6RJz0bt4BC2xB24zQjf0vXkfwXNwOfolFZmujTslJfJMk7vWpu2FbLDFSkN1cTcWbdek4-fwzIJJdmh6_wU80tUAHht6ydsBPDm1hvMB7M1MiurbfXbWR1w1-2yPzfrk1Sgz-EH-MW2QLuvEX8L4hMJIOj3JboxjrW7YsmaLSq9-1qhX6Y2tLruoGNbj4orVxALOjJ_6Kzg_Hp8dTVxLwOAqhFVLl6dSxnGqOaFKqYRGMKlThOMIIyVij8grEumnRRzJUmgd6IQLXQqp8iguc9z97sBmVVf6DTBEKX6uKFsdRbcGocxDESqeKi_iski0A2HX9Jmy2cmJJOMq69zQLjNbBcOcifsW7DEHRmuxhUnP8ZBA3PVr1sWeorbMcAF5SFD8S1A3ds43mZ81PPOy716LMb05YnGycYUOJGtJC2sMXPmfQod_Db11HRFwJCmPUwd2u7GY9T-ynioOfFi_RrVBtiBZ6XrVYCEBGe7v-QI7PkKVzx14bcZ438AIMcmi_vb-wt_BU2N6C1wv3IXN5c1Kv0cEt8yHsDH67Q_byYrX5Aiftw5Pvk6meP88ns6-_QGzFUjF
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEB5VqTgkhCBchtLuA_Spbu31-npAiCNVQpsoghTlbVmv11KrYoc6AeVP8RuZ9foQEm156bMz2qxnPPPtzvEBvEqc1PeVT23qJdJmSSxtgZHFzsIsCKmTSjfRF_rjSTA8YZ_m_nwDfje9MLqssvGJlaNOC6nvyA_0YPfI84IgfLv4YWvWKJ1dbSg0jFkcqfUvPLKVb0YfUb-vKT0czD4M7ZpVwJaIFZY2jYUIglhRDZWEDBUiJBUjxkRsJDCg-k4aCTdOA19koVKeimioslDIxA-yxNUXoOjyN5mHR5kebL4fTKafu6ISr6ISwYMNs5nrzLueoYOz_Z9C6mS5KeDUo0Pj6LJoeG8hStRRZsg1Lke_VRQ8fAD3a_hK3hl7ewgbKu_DLUNoue7D7XGdqu_D7tQMxV7vkVnX41XukV0y7cZlo0z_q67IqdqCSSP-CAYj3bjSeGZyYUp5VUmWBVnkavW9QE-un9TbJac5wX2cnpNC844TUxn_GE5uRDlPoJcXuXoGBHGRm0g9H0_303pMJCxkksbS8alII2UBa149l_U8dE3Lcc6bwrczXm_BcHXiSQk1ZsF-K7YwA0GuEwgavfKm2xX9M8eQdZ1g-C9BVdZepuQuLyl3-BenQrXOHNG_zqoxC6JWsgZSBiD9z6Lbf5leu0eEOFFMg9iCrcYWefdH2o_Tgp32MToqnX0SuSpWJS7i6VKBK36BivcxyFALnhob714wglqdw39-9eI7cGc4Gx_z49Hk6AXcNYk_z3bYFvSWFyv1EvHjMtmuP1oC327aT_wBduOBlQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB5VRVRICMHyCpTWB-ip6SbOw8kBIUS76lJaVaJFe3Mdx5FalWRpdkH71_h1zMTJRki05dJzMnKcsb_57HkBvM28PIpMxF0eZNoNs1S7Ci2LW4giFtzLtZ_Rhf7hUbx_Gn6eRJMV-N3lwlBYZYeJDVDnlaY78iEVdk-CII7FsGjDIo53Rx-mP1zqIEWe1q6dhl0iB2bxC49v9fvxLur6HeejvZNP-27bYcDVyBtmLk-ViuPUcKJNSguDbMmkyDeRJyk0rpGXJ8pP8zhShTAmMAkXphBKZ1FcZD5dhiL83xNB5NMeExPRh5cETVMRPOKEbuh7kz57aHix81NpcpvbUE4qIpom19nFh1NVo7YK22bjeh7c2MPRY3jUEln20a68J7BiygHct60tFwNYO2yd9gPYOrblsRfb7KTP9qq32RY77gtno8zgG8XmNAnCrBN_CntjSmHpMJpd2aBeU7NZxaalmX-vENPpSTtddl4ynMf5JauoAzmzMfLP4PROVPMcVsuqNC-BIUPyM02V8iizNghVFopQ81R7EVd5YhwIu18vdVsZnRp0XMouBO5CtlOwXTvxzIQac2BnKTa1pUFuE4g7vcou7xWRWqLxuk1Q_EvQ1C3e1NKXNZee_Oo1_Nab4DmA_GuhA8lSsqVUlir9z6Abfy295RyR7CQpj1MH1ru1KPsPWW5TBzaXjxGyyA-lSlPNaxwkoKCBG95AxUdobrgDL-wa738w0lvy5r-6efBNWEN0kF_GRwev4YH1AAauF67D6uxqbt4gkZxlG82OZXB21xDxBxlJhGU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunological+responses+to+pneumococcal+vaccine+in+frail+older+people&rft.jtitle=Vaccine&rft.au=Ridda%2C+I&rft.au=MacIntyre%2C+CR&rft.au=Lindley%2C+R&rft.au=Gao%2C+Z&rft.date=2009-03-04&rft.pub=Elsevier+Limited&rft.issn=0264-410X&rft.eissn=1873-2518&rft.volume=27&rft.issue=10&rft.spage=1628&rft_id=info:doi/10.1016%2Fj.vaccine.2008.11.098&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=3476786571
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X09X00071%2Fcov150h.gif